In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
President Trump signed into law a spending bill that pairs full-year fiscal year (FY) 2019 funding for Labor, Health and Human Services (LHHS) and Defense with a stopgap measure to keep other agencies funded through December—staving off a partial government shutdown on the eve of the end of the fiscal year. Here’s a breakdown of how global health and medical research funding fared.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
What global health R&D advocates need to know about the 2018 omnibus spending bill.
USAID’s latest report to Congress demonstrates how strategic R&D investments are driving positive global health outcomes and saving American taxpayers money
2018 is shaping up to be another important year for US policy related to global health and medical research. As Congress returns for a busy work session and the White House continues to roll out policy reforms, here are the top five issues GHTC will be following in 2018.
What global health R&D advocates need to know about the FY2017 budget agreement.
What global health advocates need to know about the President's "skinny" budget.
At his nomination hearings, Secretary of Health and Human Services-designee Tom Price addressed global health and infectious diseases; innovation for rare diseases; support for health innovation, NIH, and priority setting for NIH-funded research. GHTC covers what he had to say.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
On Tuesday, GHTC launched our seventh annual policy report through a congressional briefing and panel discussion. The critical role played by the US government in catalyzing global health research and development was a recurring theme, as panelists discussed the interconnectedness of global and American health and emphasized the need for new health tools to protect against outbreaks and continue progress.
The Administration announced that it will transfer nearly $600 million in remaining Ebola funds to fight the growing threat of Zika virus. But many questions remain. Where is the money going? What accounts is it coming from? And what does this mean for the Global Health Security Agenda?
The US Department of Health and Human Services (HHS) is partnering with New York–based Regeneron Pharmaceuticals, Inc. for the development of an Ebola treatment.
The US Food and Drug Administration (FDA) approved the first 3D-printed drug last week, paving the way for the technology to be used to customize medical care to individual patients.
On Thursday, March 26, 2015, the Global Health Technologies Coalition (GHTC) launched its sixth annual policy report titled Meeting the challenge, seizing the opportunity: US leadership can advance global health R&D with a luncheon and panel discussion on Capitol Hill.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
Last week, we reported on exciting policy language included in the Senate Department of Defense appropriations legislation, and earlier this summer, the House and Senate State and Foreign Operations bills also included recognition of the role that new technologies could play in advancing global health.
As the DC summer kicks into full swing, Congress has had a busy month moving forward fiscal year (FY) 2015 funding legislation for a variety of government programs including global health research and development (R&D).